| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
46,090,000 |
| Market
Cap: |
3.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0847 - $0.0847 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jaguar Health is a commercial stage pharmaceuticals company focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal distress, including chronic, debilitating diarrhea. Co.'s wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals for the global marketplace from plants or plant products used in rainforest areas. Napo's marketed drug Mytesi (crofelemer 125 mg delayed-release tablets) is an oral botanical drug product approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
317 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conte Lisa A |
CEO and President |
• • – |
2018-07-18 |
4 |
B |
$1.11 |
$1,669 |
D/D |
1,500 |
7,500 |
2.73 |
- |
|
| Siegel Jonathan B. |
Director |
– • – |
2018-07-17 |
4/A |
B |
$1.19 |
$319 |
I/I |
268 |
15,000 |
2.02 |
- |
|
| Siegel Jonathan B. |
Director |
– • – |
2018-07-17 |
4 |
B |
$1.19 |
$2,656 |
I/I |
2,232 |
9,732 |
2.1 |
- |
|
| Siegel Jonathan B. |
Director |
– • – |
2018-07-16 |
4 |
B |
$1.36 |
$10,190 |
I/I |
7,500 |
9,732 |
2.1 |
- |
|
| Burford Capital Ltd |
10% Owner |
– – • |
2017-07-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,884,245 |
|
- |
|
| Bochnowski James J |
Director |
– • – |
2017-06-28 |
4 |
B |
$0.50 |
$50,000 |
I/I |
100,000 |
797,935 |
2.1 |
- |
|
| Bochnowski James J |
Director |
– • – |
2016-02-08 |
4 |
B |
$2.50 |
$400,000 |
I/I |
160,000 |
487,576 |
2.1 |
- |
|
| Bochnowski James J |
Director |
– • – |
2015-05-18 |
4 |
A |
$0.00 |
$449,994 |
I/I |
228,688 |
327,576 |
|
- |
|
| Bvcf Iii-A, L.p. |
10% Owner |
– – • |
2015-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,483,326 |
1,522,881 |
|
- |
|
| Yang Zhi |
Director |
– • • |
2015-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,483,326 |
1,522,881 |
|
- |
|
60 Records found
|
|
Page 3 of 3 |
|
|
